Tumor Infiltrating Lymphocytes in Renal Cell Cancer

  • G. P. Haas
  • J. E. Pontes
  • A. Belldegrun
Conference paper


For the past decade the immunotherapy approach to the treatment of solid cancers resistant to conventional treatment modalities has proven to be of benefit, particularly in melanoma and metastatic renal cell cancer. Cancer patients were treated with the lymphokine interleukin-2 (IL-2) alone, or in combination with other lymphokines in order to activate the patient’s immune system against the cancer. Alternatively, autologous circulating lymphocytes obtained by leukapheresis of the patient were activated and expanded with IL-2 in vitro, leading to the generation of lymphokine-activated killer (LAK) cells. These LAK cells capable of mediating a high degree of antitumor activity were reinfused to the patients in combination with IL-2 administration, thus providing the patient with a large pool of killer cells. Following LAK cell therapy for renal cell cancer 35% partial and complete response rates have been achieved with many durable responses and several patients who are still in remission after 3 years [21].


Renal Cell Carcinoma Renal Cell Cancer Tumor Infiltrate Lymphocyte Autologous Tumor Autologous Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alexander RB, Rosenberg SA (1990) Long term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunol 145: 1615–1620PubMedGoogle Scholar
  2. 2.
    Barth RJ, Bock SN, Mule JJ, Rosenberg SA (1990) Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes. J Immunol 144: 1531PubMedGoogle Scholar
  3. 3.
    Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48: 206–214PubMedGoogle Scholar
  4. 4.
    Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA (1989) Human tumor infiltrating lymphocytes: analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142: 4520–4526PubMedGoogle Scholar
  5. 5.
    Belldegrun A, Uppenkamp A, Rosenberg SA (1990) Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid. Cancer Immunol Immunother 31 (1): 1–10PubMedCrossRefGoogle Scholar
  6. 6.
    Bukowski RM, Murthy S, Rayman P, et al. (1991) Clinical results and characterization of tumor infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 51: 4199–4205.PubMedGoogle Scholar
  7. 7.
    Cameron RB, Spiess PJ, Rosenberg SA (1990) Synergistic antitumor activity of tumor infiltrating lymphocytes, interleukin-2, and local tumor irradiation: studies on the mechanism of action. J Exp Med 171: 249–263PubMedCrossRefGoogle Scholar
  8. 8.
    Finke JH, Tubbs R, Connelly R, Pontes E, Montie J (1988) Tumor infiltrating lymphocytes in patients with renal cell carcinoma. In: Battisto J, Plate J, Shearer G (eds) Cytotoxic T cells: biology and relevance to disease. New York Academy of Science pp 387–394Google Scholar
  9. 9.
    Finke JH, Rayman P, Alexander J, et al. (1990) Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50: 2363–2370PubMedGoogle Scholar
  10. 10.
    Fisher B, Packard BS, Read EF, et al. (1989) Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7: 250–261PubMedGoogle Scholar
  11. 11.
    Griffith KD, Read EJ, Carrasquillo JA, et al. (1989) In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. JNCI 81: 1709–1717PubMedGoogle Scholar
  12. 12.
    Haas GP, Solomon D, Rosenberg SA (1990) Tumor-infiltrating lymphocytes from nonrenal urological malignancies. Cancer Immunol Immunother 30: 342–350PubMedCrossRefGoogle Scholar
  13. 13.
    Itoh K, Tilden AB, Balch CM (1986) Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46: 3011–3017PubMedGoogle Scholar
  14. 14.
    Itoh K, Platsoucas CD, Balch CM (1988) Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells and involvement of the T cell receptor. J Exp Med 168: 1419–1441PubMedCrossRefGoogle Scholar
  15. 15.
    Li WY, Lusheng S, Kanbour A, Herberman RB, Whiteside TL (1989) Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res 49: 5979–5985Google Scholar
  16. 16.
    Muul LL, Nason-Burchenal K, Hyatt C, Schwarz S, Slavin D, Director EP, Rosenberg SA (1987) Studies of serum-free culture medium in the generation of lymphokine activated killer cells J Immunol Methods 105: 183–192PubMedCrossRefGoogle Scholar
  17. 17.
    Muul LM, Spiess PJ, Director EP, Rosenberg SA (1987) Identification of specific cytolytic immune response against autologous tumor in humans bearing malignant melanoma J Immunol 138: 989–995PubMedGoogle Scholar
  18. 18.
    North RJ (1984) Gamma-irradiation facilitates the expression of adoptive immunotherapy of an established tumor by eliminating suppressor T cells. Cancer Immunol Immunother 16: 175–181PubMedCrossRefGoogle Scholar
  19. 19.
    Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with infiltrating lymphocytes. Science 233: 1318–1321PubMedCrossRefGoogle Scholar
  20. 20.
    Rosenberg SA, Packard BS, Aebersold PM, et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676–1680PubMedCrossRefGoogle Scholar
  21. 21.
    Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485PubMedCrossRefGoogle Scholar
  22. 22.
    Slingluff CL, Darrow TL, Seigler HF (1987) Human T cells specifically activated against autologous malignant melanoma. Arch Surg 122: 1207–1411Google Scholar
  23. 23.
    Spiess PJ, Yang JC, Rosenberg SA (1987) In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin 2. JNCI 75: 1067–1075Google Scholar
  24. 24.
    Stotter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT (1989) Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. J Immunol 142: 1767–1773Google Scholar
  25. 25.
    Topalian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102: 127–141PubMedCrossRefGoogle Scholar
  26. 26.
    Topalian SL, Solomon D, Rosenberg SA (1989) Tumor-specific cytolysis by lymphocytes infiltrating human melanoma. J Immunol 142: 3714–3725PubMedGoogle Scholar
  27. 27.
    Vose BM, Moore M (1985) Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 11: 27–40Google Scholar
  28. 28.
    Whiteside TL, Miescher S, Hurlimann J, Moretta L, Fliedner V von (1986) Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer 37: 803–811PubMedCrossRefGoogle Scholar
  29. 29.
    Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL (1989) Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies. J Immunol 143: 3404–3411PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • G. P. Haas
    • 1
  • J. E. Pontes
    • 1
  • A. Belldegrun
    • 2
  1. 1.Section of Urological Oncology, Department of UrologyWayne State University, School of MedicineDetroitUSA
  2. 2.Cancer Immunotherapy Program School of MedicineJonsson Comprehensive Cancer CenterLos AngelesUSA

Personalised recommendations